查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954311

免疫細胞工程市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、製程、組件、功能及設備分類

Immune Cell Engineering Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Component, Functionality, Equipment
出版日期: | 出版商: Global Insight Services | 英文 305 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，免疫細胞工程市場規模將從2024年的41億美元成長至313億美元，複合年成長率約23%。免疫細胞工程市場涵蓋用於改造免疫細胞以增強其治療效果的技術和調查方法，包括基因編輯、細胞培養最佳化以及用於治療癌症和自體免疫疾病的臨床試驗項目日益增多，也推動了該市場的發展。

免疫細胞工程市場正迅速擴張，這主要得益於細胞療法和基因工程技術的進步。 T細胞工程領域由於其在個人化癌症療法開發中的核心作用，展現出最高的成長速度。特別是CAR-T療法，因其在治療骨髓惡性腫瘤的成功而處於領先地位。 NK細胞工程緊隨其後，在腫瘤學和感染疾病治療方面均展現出巨大的潛力。這些經過基因工程改造的免疫細胞因其能夠選擇性地靶向並清除病變細胞而備受關注。基因編輯技術，特別是CRISPR-Cas9技術，對於提高免疫細胞工程的精準性和療效至關重要。這一細分領域正吸引大量的投資和研究關注。此外，遞送系統的進步，例如病毒載體和非病毒載體，對於克服基因轉移相關的挑戰至關重要。生物技術公司與學術機構之間日益密切的合作，旨在加速治療方法創新，這也推動了市場的發展。

市場區隔
按類型 T細胞工程、B細胞工程、NK細胞工程、巨噬細胞工程、樹突細胞工程、幹細胞工程
產品 細胞株、試劑及試劑盒、設備、軟體
服務 細胞治療服務、基因編輯服務、客製化開發服務、諮詢服務
科技 CRISPR、TALEN、鋅指核酸酶、睡美人轉座子、病毒載體、非病毒方法
應用領域 癌症免疫療法、自體免疫疾病、感染疾病、再生醫學、移植
最終用戶 生技公司、製藥公司、研究機構、醫院和診所
過程 體外工程、體內工程
成分 載體，質體
功能 基因敲除、基因敲入、基因調控
裝置 生物反應器、細胞分選器

免疫細胞工程市場正經歷市場佔有率、定價策略和產品創新方面的動態變化。主要企業正優先推出新產品以獲得競爭優勢。定價趨勢受到技術進步和策略聯盟的影響，從而提高了產品的可近性和可負擔性。該市場以多元化的產品組合為特徵，新興企業正憑藉創新且經濟高效的解決方案挑戰現有企業。從區域來看，北美處於市場發展的前沿，而亞太地區由於生物技術投資的增加，正在迅速追趕。從競爭格局來看，市場較為分散，成熟企業和靈活的Start-Ups都在爭奪主導。法規結構，尤其是在北美和歐洲，對塑造市場動態至關重要，嚴格的指導方針確保了產品的有效性和安全性。企業正在利用監管方面的洞察來簡化產品核可並最佳化打入市場策略。競爭基準分析顯示，企業正專注於策略聯盟和研發投資以保持競爭優勢。市場數據凸顯了個人化醫療的發展趨勢，這主要得益於基因編輯技術的進步，預計將推動市場成長。

主要趨勢和促進因素：

受基因工程和生物技術進步的推動，免疫細胞工程市場正經歷強勁成長。其中一個關鍵趨勢是CRISPR技術的整合，這項技術徹底革新了免疫細胞修飾的精準性和效率。這項創新使得開發更有效的癌症和自體免疫疾病治療方法成為可能，顯著改善了患者的治療效果。另一個關鍵趨勢是生物製藥公司與學術機構之間合作的日益密切。這些夥伴關係正在加速研發進程，推動新型治療方法的快速商業化。個人化醫療的興起也是重要的促進因素，免疫細胞工程在設計針對個別患者特徵的治療方法方面發揮關鍵作用。此外，慢性病盛行率的不斷上升也推動了對創新治療方案的需求。隨著全球醫療系統優先發展先進療法，免疫細胞工程市場預計將顯著擴張。專注於可擴展且經濟高效的生產方法的公司有望獲得競爭優勢。此外，監管支援和優惠的報銷政策正在促進市場准入和擴張，為行業相關人員提供了盈利的機會。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • T細胞工程
    • B細胞工程
    • NK細胞工程
    • 巨噬細胞工程
    • 樹突狀細胞工程
    • 幹細胞工程
  • 市場規模及預測：依產品分類
    • 細胞株
    • 試劑和試劑盒
    • 裝置
    • 軟體
  • 市場規模及預測：依服務分類
    • 細胞治療服務
    • 基因編輯服務
    • 客製化開發服務
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • CRISPR
    • TALENs
    • 鋅指核酸酶
    • 睡美人轉座子
    • 病毒載體
    • 非病毒方法
  • 市場規模及預測：依應用領域分類
    • 癌症免疫療法
    • 自體免疫疾病
    • 感染疾病
    • 再生醫學
    • 移植
  • 市場規模及預測：依最終用戶分類
    • 生技公司
    • 製藥公司
    • 研究所
    • 醫院和診所
  • 市場規模及預測：依製程分類
    • 體外工程
    • 體內工程
  • 市場規模及預測：依組件分類
    • 向量
    • 質體
  • 市場規模及預測：依功能分類
    • 基因敲除
    • 基因敲入
    • 基因調控
  • 市場規模及預測：依設備分類
    • 生物反應器
    • 細胞分選裝置

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Sangamo Therapeutics
  • Adaptimmune Therapeutics
  • Cellectis
  • Kiadis Pharma
  • Fate Therapeutics
  • Immatics Biotechnologies
  • Atara Biotherapeutics
  • Allogene Therapeutics
  • Poseida Therapeutics
  • Arcellx
  • Gritstone Oncology
  • TCR2 Therapeutics
  • Rubius Therapeutics
  • Bellicum Pharmaceuticals
  • Autolus Therapeutics
  • Glycostem Therapeutics
  • Celyad Oncology
  • Marker Therapeutics
  • Sorrento Therapeutics
  • Iovance Biotherapeutics

第9章：關於我們

簡介目錄
Product Code: GIS26627

Immune Cell Engineering Market is anticipated to expand from $4.1 billion in 2024 to $31.3 billion by 2034, growing at a CAGR of approximately 23%. The Immune Cell Engineering Market encompasses technologies and methodologies for modifying immune cells to enhance their therapeutic efficacy. This includes gene editing, cell culture optimization, and delivery systems aimed at treating diseases such as cancer and autoimmune disorders. Advances in CRISPR and CAR-T cell therapies are propelling growth, with a focus on precision medicine and personalized treatments. The market is driven by increasing investment in biotechnology and a growing pipeline of clinical trials seeking to harness the body's immune system to combat complex diseases.

The Immune Cell Engineering Market is expanding rapidly, fueled by advancements in cellular therapies and genetic engineering technologies. The T-cell engineering segment is the top performer, driven by its pivotal role in developing personalized cancer treatments. CAR-T therapies, specifically, are at the forefront due to their success in treating hematological malignancies. The NK cell engineering segment follows closely, as it offers promising potential in both oncology and infectious disease applications. These engineered immune cells are gaining traction for their ability to target and eliminate diseased cells selectively. Gene editing technologies, particularly CRISPR-Cas9, are instrumental in enhancing the precision and efficacy of immune cell engineering. This sub-segment is witnessing substantial investment and research focus. Furthermore, advancements in delivery systems, such as viral vectors and non-viral methods, are critical in overcoming challenges associated with gene transfer. The market is poised for growth with increasing collaborations between biotech firms and academic institutions, aiming to accelerate therapeutic innovation.

Market Segmentation
TypeT-Cell Engineering, B-Cell Engineering, NK-Cell Engineering, Macrophage Engineering, Dendritic Cell Engineering, Stem Cell Engineering
ProductCell Lines, Reagents and Kits, Instruments, Software
ServicesCell Therapy Services, Gene Editing Services, Custom Development Services, Consultation Services
TechnologyCRISPR, TALENs, Zinc Finger Nucleases, Sleeping Beauty Transposon, Viral Vectors, Non-Viral Methods
ApplicationCancer Immunotherapy, Autoimmune Disorders, Infectious Diseases, Regenerative Medicine, Transplantation
End UserBiotechnology Companies, Pharmaceutical Companies, Research Institutes, Hospitals and Clinics
ProcessEx Vivo Engineering, In Vivo Engineering
ComponentVectors, Plasmids
FunctionalityGene Knockout, Gene Knock-In, Gene Regulation
EquipmentBioreactors, Cell Sorters

The Immune Cell Engineering Market is witnessing dynamic shifts in market share, pricing strategies, and product innovations. Leading companies are prioritizing novel product launches to capture competitive advantage. Pricing trends are influenced by technological advancements and strategic partnerships, which are enhancing product accessibility and affordability. The market is characterized by a diverse range of offerings, with emerging players challenging established entities through innovative, cost-effective solutions. Geographically, North America remains at the forefront of market developments, with Asia-Pacific regions rapidly catching up due to increased investments in biotechnology. In terms of competition, the market is fragmented with both established giants and nimble startups vying for dominance. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent guidelines ensuring product efficacy and safety. Companies are leveraging regulatory insights to streamline product approvals and enhance market entry strategies. Competitive benchmarking reveals a focus on strategic alliances and R&D investments to maintain a competitive edge. Market data indicates a trend towards personalized medicine, driven by advancements in gene editing technologies, which are expected to propel market growth.

Geographical Overview:

The Immune Cell Engineering Market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in biotechnology research. The presence of major biotech firms and innovative startups further propels the region's market dominance. Europe follows closely, with robust government support for research and development in cellular therapies enhancing market growth. The region's strong regulatory framework and emphasis on precision medicine contribute to its appeal. In Asia Pacific, the market is expanding rapidly, bolstered by increasing healthcare investments and a burgeoning biotech sector. Countries like China and Japan are emerging as key players, with significant advancements in genetic engineering technologies. Latin America and the Middle East & Africa are also witnessing growth. Brazil and Israel are notable emerging markets, driven by rising investments in healthcare innovation and supportive governmental policies. These regions offer lucrative opportunities for market expansion and collaboration.

Global tariffs and geopolitical tensions are significantly influencing the Immune Cell Engineering Market, particularly in East Asia. Japan and South Korea are navigating US-China trade tensions by enhancing domestic biotech capabilities and diversifying supply chains. China's strategy focuses on self-reliance, investing heavily in indigenous biotech innovations to mitigate export restrictions. Taiwan, a key player in biotech manufacturing, faces geopolitical risks but remains vital due to its advanced capabilities. The global Immune Cell Engineering Market is experiencing robust growth, driven by rising demand for personalized medicine and advancements in gene editing technologies. By 2035, the market is poised for substantial expansion, contingent on geopolitical stability and resilient supply chains. Middle East conflicts could indirectly affect the market by influencing global energy prices, impacting operational costs.

Key Trends and Drivers:

The Immune Cell Engineering Market is experiencing robust growth, driven by advances in genetic engineering and biotechnology. Key trends include the integration of CRISPR technology, which is revolutionizing the precision and efficiency of immune cell modifications. This innovation is enabling the development of more effective therapies for cancer and autoimmune diseases, significantly enhancing patient outcomes. Another major trend is the increasing collaboration between biopharmaceutical companies and academic institutions. These partnerships are accelerating research and development efforts, leading to faster commercialization of novel therapies. The rise of personalized medicine is also a crucial driver, with immune cell engineering playing a pivotal role in tailoring treatments to individual patient profiles. Additionally, the growing prevalence of chronic diseases is fueling demand for innovative therapeutic solutions. As healthcare systems globally prioritize advanced treatments, the immune cell engineering market is poised for substantial expansion. Companies focusing on scalable and cost-effective production methods are likely to gain a competitive advantage. Furthermore, regulatory support and favorable reimbursement policies are facilitating market entry and expansion, providing lucrative opportunities for industry stakeholders.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 T-Cell Engineering
    • 4.1.2 B-Cell Engineering
    • 4.1.3 NK-Cell Engineering
    • 4.1.4 Macrophage Engineering
    • 4.1.5 Dendritic Cell Engineering
    • 4.1.6 Stem Cell Engineering
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Lines
    • 4.2.2 Reagents and Kits
    • 4.2.3 Instruments
    • 4.2.4 Software
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cell Therapy Services
    • 4.3.2 Gene Editing Services
    • 4.3.3 Custom Development Services
    • 4.3.4 Consultation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 TALENs
    • 4.4.3 Zinc Finger Nucleases
    • 4.4.4 Sleeping Beauty Transposon
    • 4.4.5 Viral Vectors
    • 4.4.6 Non-Viral Methods
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Cancer Immunotherapy
    • 4.5.2 Autoimmune Disorders
    • 4.5.3 Infectious Diseases
    • 4.5.4 Regenerative Medicine
    • 4.5.5 Transplantation
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Hospitals and Clinics
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Ex Vivo Engineering
    • 4.7.2 In Vivo Engineering
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Vectors
    • 4.8.2 Plasmids
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Gene Knockout
    • 4.9.2 Gene Knock-In
    • 4.9.3 Gene Regulation
  • 4.10 Market Size & Forecast by Equipment (2020-2035)
    • 4.10.1 Bioreactors
    • 4.10.2 Cell Sorters

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Functionality
      • 5.2.1.10 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Functionality
      • 5.2.2.10 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Functionality
      • 5.2.3.10 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Functionality
      • 5.3.1.10 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Functionality
      • 5.3.2.10 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Functionality
      • 5.3.3.10 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Functionality
      • 5.4.1.10 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Functionality
      • 5.4.2.10 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Functionality
      • 5.4.3.10 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Functionality
      • 5.4.4.10 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Functionality
      • 5.4.5.10 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Functionality
      • 5.4.6.10 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Functionality
      • 5.4.7.10 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Functionality
      • 5.5.1.10 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Functionality
      • 5.5.2.10 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Functionality
      • 5.5.3.10 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Functionality
      • 5.5.4.10 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Functionality
      • 5.5.5.10 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Functionality
      • 5.5.6.10 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Functionality
      • 5.6.1.10 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Functionality
      • 5.6.2.10 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Functionality
      • 5.6.3.10 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Functionality
      • 5.6.4.10 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Functionality
      • 5.6.5.10 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sangamo Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Adaptimmune Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cellectis
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Kiadis Pharma
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Fate Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Immatics Biotechnologies
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Atara Biotherapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Allogene Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Poseida Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Arcellx
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Gritstone Oncology
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 TCR2 Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Rubius Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bellicum Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Autolus Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Glycostem Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Celyad Oncology
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Marker Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Sorrento Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Iovance Biotherapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us